Clinical trials: B Cell
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
- Trial name
- NCT03913949
- Testing
- APG-2575
- Where
- 5 sites in China
- Volunteers
- 74 people
- Sponsor
- Ascentage Pharma Group Inc.
CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT06979076
- Testing
- MS-553, DS1, MS-553, DS2
- Volunteers
- 12 people
- Sponsor
- MingSight Pharmaceuticals, Inc
Small Cell Lung Cancer, Uveal Melanoma
A Study of PLX2853 in Advanced Malignancies.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
- Conditions
- Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT03297424
- Testing
- PLX2853
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Opna Bio LLC
Marginal Zone Lymphoma
Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma
This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care.
- Trial name
- NCT07777120
- Testing
- lisocabtagene maraleucel
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms by Site, Lymphoma, Non-hodgkin
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer.
- Conditions
- Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT00562224
- Testing
- PCI-24781
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pharmacyclics LLC.
Multiple Sclerosis, Relapsing Forms
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
- Trial name
- NCT01585766
- Testing
- MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, MEDI-551 100 MG-IV
- Where
- 16 sites in United States, Poland and 2 more
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Diffuse Large B-cell Lymphoma
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05192486
- Testing
- GNC-038
- Where
- 4 sites in China
- Volunteers
- 12 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neuromyelitis Optica Spectrum Disorders
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.
- Trial name
- NCT03330418
- Testing
- RC18 160 mg
- Where
- China
- Volunteers
- 178 people
- Sponsor
- RemeGen Co., Ltd.
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part…
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- MT-3724NHL001 (NCT02361346)
- Testing
- MT-3724 Phase 1, MT-3724 Phase 2
- Where
- 41 sites in United States, Belarus and 8 more
- Volunteers
- 38 people
- Sponsor
- Molecular Templates, Inc.
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Haemophilus Influenzae Type b, Diphtheria
Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
The purpose of this study is to compare the immune response, safety and reactogenicity of Tritanrix™-HepB/Hib-MenAC vaccine given either with or without a birth dose of hepatitis B vaccine to Tritanrix™-HepB/Hiberix™ when given…
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Whole Cell Pertussis, Hepatitis B
- Trial name
- NCT00290303
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 996 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
B-Cell Chronic Lymphocytic Leukemia
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)
This is a multi-center, open-label, single arm Phase 1/2 study evaluating the feasibility, safety, and tolerability of a series of 16 immunizations of Id-KLH with GM-CSF in patients with previously untreated B-CLL.
- Trial name
- NCT00302861
- Testing
- MyVax
- Volunteers
- 86 people
- Sponsor
- Genitope Corporation
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and…
- Trial name
- NCT06788639
- Testing
- Lisocabtagene maraleucel
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
B-cell Acute Lymphoblastic Leukemia
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- B-ALL (NCT06009107)
- Testing
- HY004, Cyclophosphamide, Fludarabine Phosphate
- Sponsor
- Juventas Cell Therapy Ltd.
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with…
- Conditions
- Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT02825836
- Testing
- TL-895, Navtemadlin
- Where
- 17 sites in United States, Hungary and 5 more
- Volunteers
- 130 people
- Sponsor
- Telios Pharma, Inc.
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Lymphoma
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with…
- Trial name
- NCT02257567
- Testing
- Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid)
- Where
- 62 sites in United States, Australia and 11 more
- Volunteers
- 331 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with…
- Trial name
- MURANO (NCT02005471)
- Testing
- Bendamustine, Venetoclax, Rituximab
- Where
- 111 sites in United States, Australia and 18 more
- Volunteers
- 389 people
- Sponsor
- Hoffmann-La Roche
HCC, Hepatitis B Virus Related Hepatocellular Carcinoma
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
- Conditions
- HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT06617000
- Testing
- SCG101
- Where
- 7 sites in China
- Volunteers
- 38 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
- Trial name
- NCT07154264
- Testing
- DZD8586, Venetoclax
- Where
- 15 sites in China
- Volunteers
- 66 people
- Sponsor
- Dizal Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.